| Name | Gap junction beta-2 protein | ||
| UniProt ID | CXB2_HUMAN | ||
| Gene Name | GJB2 | ||
| Gene ID | 2706 | ||
| Synonyms |
GJB2, BAPS, CX26, DFNA3, DFNA3A, DFNB1, DFNB1A, HID, KID, NSRD1, PPK
|
||
| Sequence |
MDWGTLQTILGGVNKHSTSIGKIWLTVLFIFRIMILVVAAKEVWGDEQADFVCNTLQPGC
KNVCYDHYFPISHIRLWALQLIFVSTPALLVAMHVAYRRHEKKRKFIKGEIKSEFKDIEE IKTQKVRIEGSLWWTYTSSIFFRVIFEAAFMYVFYVMYDGFSMQRLVKCNAWPCPNTVDC FVSRPTEKTVFTVFMIAVSGICILLNVTELCYLLIRYCSGKSKKPV |
||
| Pathway Map | MAP LINK | ||
| T.C. Number | 1.A.24.1.3 | ||
| KEGG ID | hsa2706 | ||
| TTD ID | T88947 | ||
| Pfam | PF00029 | ||
| Pair Name | Methylselenocysteine, Etoposide | |||
| Phytochemical | Methylselenocysteine | |||
| Drug | Etoposide | |||
| Disease Info | [ICD-11: 2C77.Z] | Cervical cancer | Investigative | |
| Regulate Info | Up-regulation | Gap junction beta-2 protein | Expression | |
| Result | We provide the novel finding that MSC increases etoposide-mediated cytotoxicity by enhancing GJ activity, due to elevated Cx expression through a GSH-dependent posttranscriptional mechanism. More generally, the study highlights potential benefit of the combination of GJ modulators and chemotherapeutic agents in anticancer treatment. | |||
